Related Experiment Video
Updated: Jun 26, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
Published on: December 7, 2014
Recurrent refractory arterial thromboembolism associated with the Janus kinase 2 V617F mutation
Faisal R Ali1, Lara N Roberts, Hiren Mistry
1Department of Vascular Surgery, Kings College Hospital, London, United Kingdom. faisal.ali@kch.nhs.uk
Abstract:
We report two patients with peripheral vascular disease requiring multiple bilateral radiologic and surgical interventions, and whose disease was unresponsive to conventional anticoagulation and antiplatelet therapy. Although thrombocytosis was only intermittent, analysis of the Janus kinase 2 (JAK2) gene revealed a V617F mutation, thus confirming the presence of an underlying occult myeloproliferative disorder. We propose that JAK2 mutation analysis be considered in patients with recurrent, unexplained arterial events to identify those with occult myeloproliferative disorders.
Related Concept Videos
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Venous Thrombosis I: Introduction
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
Pulmonary Embolism I: Introduction
